Why the study?
Do potassium binders reduce serum potassium and allow maintenance of RAAS inhibitors in patients with heart failure and hyperkalaemia?
Do potassium binders reduce serum potassium and allow maintenance of RAAS inhibitors in patients with heart failure and hyperkalaemia?
Answers are grounded in this paper and cite their sources.
Potassium binders effectively lower serum potassium in heart failure patients, potentially enabling the continuation of life-saving RAAS inhibitor therapy.
This article refers to ‘Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial’†, by S. D. Anker et al., and ‘Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors’†, by B. Pitt et al., published in this issue, European Journal of Heart Failure (2015); 17: 1050–1065. Antagonism of neurohormonal systems have driven the greatest pharmacological improvement in the natural history of patients with heart failure and reduced left ventricular ejection fraction. However, these actions come with some cost and limitation. Both beta adrenergic receptor blockers and renin–angiotensin–aldosterone system inhibitors (RAASi) may cause hypotension. RAASi may cause renal impairment, and angiotensin converting enzyme inhibitors (ACEi) may cause cough and angioedema. Each of these classes of agents may contribute to hyperkalaemia. LCZ-696, a dual angiotensin receptor blocker (ARB)/neprilysin inhibitor, recently shown to improve clinical outcomes compared with enalapril, at 20 mg daily, may also provoke intolerance as a result of these same adverse effects (with hypotension more prevalent, but renal impairment, cough, and hyperkalaemia less prevalent than with enalapril in the dose administered),1 Occurrence of any of these adverse events may limit the use, and therefore the effectiveness, of neurohormonal antagonists. The addition of mineralocorticoid receptor antagonists (MRA) to beta blockers and either ACEi or ARB2-4 has been shown to improve clinical outcomes, including all-cause mortality. However, with the widespread use of these agents, concern has been raised regarding an increased incidence of life-threatening hyperkalaemia5 A rising potassium level represents a frequent cause for RAASi dose reduction or discontinuation—actions that may deprive patients of therapy proven to improve clinical outcomes.6, 7 Although optimal dosing of MRA for outcome benefit has not been explored, for other RAAS antagonists the clinical benefit has been shown to be dose dependent.8 For these reasons, management of the adverse effects of RAASi, without reducing or eliminating the dose of the therapeutic agent, represents an attractive goal. The recent availability of safe and tolerable gastrointestinal (GI) potassium binders is changing the approach to managing hyperkalaemia, regardless of cause.9, 10 In this issue, two groups report the effects of two agents—patiromer, an oral potassium-binding polymer, and sodium zirconium cyclosilicate (ZS-9), a selective potassium ion trap—on serum potassium levels in the subsets of patients with heart failure participating in phase III investigations.11, 12 Anker et al.11 report results from 94 patients with heart failure participating in the Hyperkalaemia Randomized Intervention Multidose ZS-9 Maintenance (HARMONIZE) trial, examining effects of ZS-9 on serum potassium levels in patients with baseline levels ≥5.1 mmol/L. Among these patients, 93% achieved the target potassium level of 3.5–5 mmol/L within 48 h of receiving open label ZS–9. With randomization of responders to placebo (ZS-9 withdrawal) or one of three doses of ZS-9 for 4 weeks, there was a dose-related, sustained serum potassium reduction among the active treatment groups, compared with the original baseline and with placebo. These findings occurred in the absence of changes in concomitant medications (per protocol). However, the authors infer that, in practice, administration of ZS-9 would have allowed maintenance of RAASi dosing, which otherwise would have frequently been decreased or eliminated. Pitt et al.12 report a similar analysis of a 102-patient heart failure subgroup from the Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalaemia (OPAL-HK), examining effects of two doses of patiromer on serum potassium levels in patients with class 3 or 4 chronic kidney disease, serum potassium 5.1 to <6.5 mmol/L, with stable RAASi dosing. The heart failure subgroup performed similarly to the remaining population, reducing serum potassium by an average of approximately 1 mmol/L during a 4-week initial phase. During a subsequent single-blind phase in patients who had achieved normokalaemia, those randomized to withdraw had a greater 4-week increase in serum potassium than did patients continuing patiromer (median increase 0.74 vs. 0.10 mmol/L). In a pre-specified exploratory analysis, patients receiving placebo were less likely to continue receiving RAASi than those receiving patiromer (55% vs. 100% at the end of the study). These two analyses confirm that patients with heart failure and elevated serum potassium have similar responses to potassium binding agents, in terms of reducing serum potassium, as patients without heart failure. Each of these analyses has its strengths and limitations. In the HARMONIZE trial, maintenance on RAASi was not an entry criterion. Sixty-nine per cent of patients were receiving RAASi, although only 11% were receiving an MRA. The randomized phase of the study was double blind and did not allow for adjustment of concomitant medications, but called for discontinuation for any patients with serum potassium >6.2 mmol/L, although such event apparently did not occur. So, although Anker et al.11 reasonably infer that ZS-9 treatment may enable RAASi use, they do not present direct evidence to that effect. In OPAL-HK, entry into both the initial phase and the randomized phase required prescription of RAASi. During the initial 4 weeks, there were no RAASi dose adjustments, unless serum potassium was ≥6.5 mmol/L, in order to facilitate analysis of patiromer effect on serum potassium. During the first 4 weeks of the randomized phase, hyperkalaemia was defined as serum potassium ≥5.5 mmol/L, with dosing change only occurring if this definition was met. During the second 4 weeks, hyperkalaemia was redefined as serum potassium ≥5.1 mmol/L. Far more patients reached this threshold when randomized to placebo vs. patiromer, and the analysis by Pitt et al.12 provides direct evidence of a greater proportion of patients remaining on RAASi in the latter group. Given the single-blind nature of the intervention, it is possible that investigator bias may have influenced the difference in RAASi maintenance. Such bias was minimized by pre-specification of an algorithm for change of medication based on the magnitude of serum potassium elevation to >5.5 mmol/L. As expected, patiromer was increased in patients randomized to this agent, whereas RAASi was primarily decreased in the placebo group. Findings from both of these studies suggest an over-reaction to serum potassium levels within clinical practice. Over 4 weeks, in each trial, patients were allowed to have serum potassium levels as high as 6.2 mmol/L (HARMONIZE) or 6.5 mmol/L (OPAL-HK) without intervention and, apparently, they tolerated these levels without difficulty. These findings strongly suggest that down-titration of RAASi in response to lower levels of hyperkalaemia may be unnecessarily conservative for most patients, as long as potassium levels and kidney function are carefully monitored. Understandably, investigators within a carefully monitored clinical trial might be more comfortable with mild to moderate hyperkalaemia than would clinicians in practice. So, despite these caveats and cautions in interpreting the data, each of these studies lends credence to the view that potassium-binding agents have the potential to increase utilization of RAASi as, in practice, clinicians may well limit use of these agents with potassium levels in the range of 5.1–5.9 mmol/L. Despite the promise of these two analyses, more work is needed to determine whether deploying potassium-binding agents to expand the use of RAASi in hyperkalaemic heart failure patients would translate into improved clinical outcomes. It is possible that an increase in serum potassium levels contributes to the beneficial mechanism of RAASi, particularly reduced rates of sudden cardiac death with the administration of MRA.2, 3. If so, then negating the potassium-sparing effect of MRA may detract from some of its benefit. However, this possibility is rendered less likely by analysis of EPHESUS trial results, indicating that outcome benefits of eplerenone following myocardial infarction are independent of the benefits of potassium sparing, as seen in both treatment groups.13 There are also data from the RALES and EPHESUS databases suggesting that with higher baseline levels of serum potassium (within the range allowable by protocol) cardiovascular mortality is lower and the benefit of MRA diminishes.14 Higher baseline serum potassium levels may signify reduced endogenous mineralocorticoid receptor activation, providing less opportunity for MRA to provide clinical benefit. In contrast, post-hoc analyses of the RALES and EMPHASIS-HF trials show that the outcome benefits with MRA, compared with placebo, were maintained in patients who developed moderate hyperkalaemia (potassium levels between 5.5 mmol/L and 6.0 mmol/L) during treatment (Figure 1).6, 7 Presumably, once patients manifest potassium levels in this range, many had study drug and/or concomitant RAASi reduced or discontinued, begging the question whether treatment benefit might have been further augmented if potassium binders had reduced serum potassium, thereby facilitating preservation of RAASi dosing. Maintenance of RAASi through lowering serum potassium levels cannot necessarily be assumed to translate into clinical benefit. However, these two reports raise the possibility of substantial clinical benefit to be derived from the appropriate use of potassium-binding agents. The findings call for additional investigation to determine the impact of such use on clinical outcomes in patients with heart failure. Consideration should be given to effectiveness trials comparing outcomes in patients in whom MRA is prescribed, randomized to the strategy of either reducing RAASi dosing or adding a potassium-binding agent in the setting of hyperkalaemia. The potential also exists for demonstrating greater benefit from more aggressive RAASi, with higher drug doses, achievable through more liberal use of potassium binders. With the availability of these newer, safer, more tolerable potassium-binding agents and the demonstrated potential for retaining higher use of RAASi, it is important to take the next step and explore a connection between the pharmacodynamics of these agents, and reduced morbidity and mortality, through well-designed, prospective randomized clinical trials in patients with heart failure. Conflict of interest: Consultant to ZS Pharma.
No takes yet. Share an insight, caveat, or question.
Marvin A. Konstam (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: